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A study was undertaken to describe the treatment preferences and choices of patients with breast cancer, and to identify predictors
of undergoing breast-conserving therapy (BCT) or mastectomy (MT). Consecutive patients with stage I/II breast cancer were eligible.
Information about predictor variables, including socio-demographics, quality of life, patients’ concerns, decision style, decisional
conflict and perceived preference of the surgeon was collected at baseline, before decision making and surgery. Patients received
standard information (n¼88) or a decision aid (n¼92) as a supplement to support decision making. A total of 180 patients
participated in the study. In all, 72% decided to have BCT (n¼123); 28% chose MT (n¼49). Multivariate analysis showed that what
patients perceived to be their surgeons’ preference and the patients’ concerns regarding breast loss and local tumour recurrence
were the strongest predictors of treatment preference. Treatment preferences in itself were highly predictive of the treatment
decision. The decision aid did not influence treatment choice. The results of this study demonstrate that patients’ concerns and their
perceptions of the treatment preferences of the physicians are important factors in patients’ decision making. Adequate information
and communication are essential to base treatment decisions on realistic concerns, and the treatment preferences of patients.
British Journal of Cancer (2004) 90, 2123–2130. doi:10.1038/sj.bjc.6601835 www.bjcancer.com
Published online 4 May 2004
& 2004 Cancer Research UK
Keywords: breast cancer; treatment decision making; decision aids
                                               
In stage I/II breast cancer, breast-conserving therapy (BCT) is
equivalent to mastectomy (MT) in terms of survival (Fisher et al,
2002; Veronesi et al, 2002). Moreover, studies comparing quality of
life (QL) after BCT or MT have consistently found an effect on
body image but failed to demonstrate overall differences (Kiebert
et al, 1991; Goodwin et al, 2003). In the absence of survival and
major QL differences, the treatment decision can be made accord-
ing to the patient’s preference (Goldhirsch et al, 2003). Hence,
shared decision making is increasingly being proposed as the pre-
ferred model of decision making in breast cancer (Charles et al, 2003).
Greater understanding of patients’ treatment preferences may
establish better and more effective decision making among
patients and physicians. Several, mainly North-American studies
identified a range of factors influencing breast cancer patients’
treatment preferences. For example, age and education were
associated with increased BCT use (Cyran et al, 2001; Morrow et al,
2001; Nold et al, 2001; Gilligan et al, 2002; Staradub et al, 2002). In
addition, patients’ concerns about recurrence, survival, body
image and radiation were found to influence treatment preferences
(Ward et al, 1989; Kotwall et al, 1996; Stafford et al, 1998;
Mastaglia and Kristjanson, 2001; Nold et al, 2001). Other,
nonpatient factors influencing treatment decisions, include
living-area (e.g. rural vs urban), type of hospital, and availability
of radiation facilities (Mastaglia and Kristjanson, 2001; Morrow
et al, 2001; Gilligan et al, 2002). Moreover, the preference of the
surgeon was a major factor in patients’ decision making (Kotwall
et al, 1996; Stafford et al, 1998; Cyran et al, 2001; Mastaglia and
Kristjanson, 2001; Nold et al, 2001).
While the above studies help to understand patients’ treatment
preferences, each has a shortcoming. For example, factors
influencing decision making in breast cancer have almost
exclusively been identified in North-American, retrospective,
surveys (Ward et al, 1989; Kotwall et al, 1996; Stafford et al,
1998; Cyran et al, 2001; Mastaglia and Kristjanson, 2001; Morrow
et al, 2001; Nold et al, 2001; Gilligan et al, 2002). In these studies,
unrecognised factors, patient recall and causality are significant
problems. Moreover, in the above studies, patients were eligible for
BCT and MT on the basis of clinical selection criteria. However,
whether patients were explicitly given the opportunity to make a
treatment choice was frequently unclear (Stafford et al, 1998;
Cyran et al, 2001; Mastaglia and Kristjanson 2001; Morrow et al,
2001; Nold et al, 2001; Gilligan et al, 2002). In addition, in the
above studies, the type and amount of patient education given to
patients was frequently not specified.
To improve our knowledge about treatment decision making in
breast cancer, the current study used a prospective design, and
patients were truly given a choice between BCT and MT. Moreover,
all patients received patient education about both treatment
options. For this purpose, a decision aid was developed and given
to half of the sample. Decision aids have been found to improve
patients’ knowledge, diminish decisional conflict and improve
realistic explanations (Molenaar et al, 2000; O’Connor et al, 2003).
However, the effect of decision aids on treatment decisions has not
been studied to a great extent.
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lThe following research questions are addressed: (1) What are
the treatment preferences and treatment decisions of women with
stage I/II breast cancer, having a choice between BCT and MT?; (2)
Which factors are predictive of patients’ treatment preferences and
decisions?; and (3) Does the use of a decision aid, have an impact
on the patients’ treatment decision?
PATIENTS AND METHODS
Patients
Consecutive patients with proven stage I/II breast cancer, for whom
BCT and MT were acceptable treatment options (judged by surgeon)
were eligible. Insufficient understanding of Dutch language was the
only exclusion criterion used.
Decision aid
The decision aid was described previously (Molenaar et al, 2001a, b).
Its format is interactive, and its informational content is arranged
in a home page which depicts nine modules (Figure 1). A module is
devoted to each treatment option, explaining potential outcomes,
benefits and disadvantages.
Hospitals
Three hospitals participated. One was a cancer hospital (NKI,
Amsterdam) and two were general hospitals (St Anna, Geldrop;
MST, Enschede). NKI and MST are teaching hospitals with a
radiation department on site. Patients from St Anna receive
radiation in a neighbouring clinic (5 miles outside Geldrop).
Study design
The current study stems from a formal evaluation in which
the effects of the decision aid on treatment decision, satisfaction
and QL were investigated (Molenaar et al, 2001b). A standard
randomisation design was considered inappropriate as the avail-
ability of the decision aid would likely contaminate standard
procedures. Therefore, a quasi-experimental design was used.
Three inclusion periods of 6 months were created in each hospital
(Table 1). Depending on time period a decision aid was available.
Patients in the control periods received standard care (i.e. oral
explanations by the surgeon, supplemented with written materials).
Procedure
The surgeon asked patients to participate once they had discussed
diagnosis and treatment. Patients received a written questionnaire,
including an informed consent form. This questionnaire was
completed before the treatment decision was made (for all
patients), and before the decision aid was provided to patients
in the decision aid condition. When present, patients used
the decision aid within a week at the outpatient department.
A nurse was present to provide support, for example with
the computer equipment, if necessary. The nurses did not
provide patient education. The choice of treatment was made
at the day of the patients’ admission to the hospital for surgery
for both groups.
Predictor variables
The following predictor variables were included: socio-demo-
graphic patient characteristics; QL; patients’ attitudes towards
treatment outcomes; patients’ decision style; decisional conflict;
patients’ perceptions of the surgeons’ treatment preferences and
having seen the decision aid or not.
Socio-demographic characteristics including age, education,
having a relationship, children and work (Table 1) were obtained
by means of the written questionnaire.
Generic QL was assessed with the MOS-20 (Kempen et al, 1995),
which measures six aspects of QL and an additional energy scale
(Table 2) (Stewart and Ware, 1992). QL scores were converted to a
0–100 scale. Higher scores indicate better QL, except for pain
where a higher score indicates more pain. The MOS-20 has
adequate levels of reliability and validity and was translated into
Dutch according to standard forward–backward procedures.
Figure 1 Main menu of decision aid. Legend: Borstsparend¼breast-conserving therapy; Borstamputatie¼mastectomy; Bestraling-radiation therapy;
Herstel¼recovery; Introductie¼introduction; Uitzaaiingen¼metastasis; Lotgenoten¼fellow patients; Vormherstel¼reconstruction; Wat is kanker¼what
is cancer?
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lFour subscales of the EORTC QLQ-BR23 were administered to
assess breast cancer-specific QL. The psychometric quality of this
instrument is well established (Sprangers et al, 1996). Response
scales were transformed to a 0–100 scale. Higher score indicate
better body image, sexual functioning, future perspective and
having more breast symptoms.
Patients’ attitudes regarding treatment outcomes were assessed.
Patients’ concern about losing a breast was assessed with a single
item (‘To what extent does the prospect of loosing your breast
upset you?’) with a 10-point Likert type response format (‘very
little’ to ‘very much’). Aversive feelings towards radiation were
assessed with three items (e.g. ‘To what extent does it bother you
that radiation may cause side effects?’) employing a 10-point
response scale. The three items were combined to obtain a
composite score. Patients’ concern for local tumour recurrence was
measured with a single question (‘How concerned would you be
about the recurrence of a tumour in the breast?’) using a 5-point
answering scale (‘very little’ to ‘very much’).
The patients’ Decision Style was assessed with The Michigan
Assessment of Decision Style (Pierce, 1995). The MADS is
developed for decision making in early stage breast cancer, and is
well validated. It was translated into Dutch language for the current
study by two bilingual individuals, using a forward–backward
translation procedure. It covers: (1) avoidance (four items,
e.g. ‘I prefer not knowing the possibility that unexpected things
could happen to me’); (2) deferring responsibility (three items,
e.g. ‘I would follow the recommendations of my physician’);
(3) information seeking (four items, e.g. ‘I would spend as
much time as I could gathering information’); and (4) deliberation
(five items, e.g. ‘I would carefully consider the risks of each option
as I was making a choice’). Scores range from 0 to 100, with higher
scores indicating more avoidance, deferring, information seeking
and deliberation.
Two subscales of the Decisional Conflict Scale were used
(O’Connor, 1995). The subscale ‘uncertainty’ refers to the level of
uncertainty a patient perceives concerning the decision (three
items, e.g. ‘This decision is hard for me to make’). The subscale
‘factors contributing to uncertainty’ (nine items, e.g. ‘I need more
advice and information about the treatment alternatives’) mea-
sures the extent to which certain factors contribute to decision
uncertainty, such as lack of information, unclear values and
emotional distress. The DCS has proven to be valid and reliable in
different health-care decision-making contexts (O’Connor, 1995).
The Dutch version of the DCS was translated, using a forward–
backward procedure, and was found to be reliable and valid
(Koedoot et al, 2001). Decisional conflict ranges from 1 to 5.
Higher scores indicate more decisional conflict.
Finally, patients were asked what they thought to be their
Surgeons’ treatment preference on a 5-point answering scale
(‘definitely BCT’ to ‘definitely MT’).
Dependent variables
Patients’ baseline Treatment Preference and the actual Treatment
Decision were the dependent variables. Treatment preferences
were measured at baseline with a single question on a 5-point
Table 1 Study design and sample size
Hospital/Period
a Period 1 Period 2 Period 3 Total
1 Standard (n¼29) Decision aid (n¼40) Standard (n¼20) 89
2 Decision aid (n¼16) Standard (n¼13) Decision aid (n¼17) 46
3 Standard (n¼14) Decision aid (n¼19) Standard (n¼12) 45
Total 59 72 49 180
aNumber of patients per hospital and period given within parentheses. Total patients per group: Decision aid: n¼92; Standard information: n¼88.
Table 2 Patients’ background characteristics at baseline (n¼180)
Patient characteristics (n¼180) Range n (%)
Hospital —
St. Anna 46 (26)
NKI/AvL 89 (49)
MST 45 (25)
Age (median; min–max) 54; 29–85
Education —
oCompulsory 16 (09)
Compulsory 98 (54)
4Compulsory; ouniversity 35 (19)
University 31 (17)
Married/partner; not married/no partner 119 (66); 61 (34)
Lives alone; with spouse/partner 44 (24); 136 (76)
Has child(ren); no child(ren) 148 (82); 32 (18)
Has child(ren) at home; no child(ren) at home 108 (60); 66 (37)
a
Employed; unemployed 97 (54); 83 (46)
Generic QoL (mean; stdev) 0–100
General health 57.8723.9
Physical functioning 83.4722.2
Pain 17.4720.5
Role functioning 79.7732.8
Social functioning 84.8725.1
Psychological functioning 58.7721.7
Energy 64.8722.7
Breast cancer-specific QoL (mean; stdev) 0–100
Body image 90.7714.7
Sexual functioning 24.9723.2
Breast symptoms 16.7716.1
Future perspective 47.3730.4
Concern losing a breast (mean; stdev) 1–10 7.673.0
Aversion radiotherapy (mean; stdev) 1–10 6.572.5
Concern local recurrence (mean; stdev) 1–5 3.771.1
Decision style (mean; stdev) 0–100
Avoidance 21.8719.0
Deferring responsibility 82.3717.5
Information seeking 56.2729.3
Deliberation 88.0716.0
Decisional conflict (mean; stdev) 1–5
Decision uncertainty 2.871.1
Factors contributing to uncertainty 2.570.7
Patients’ treatment preference —
BCT 114 (63)
Unsure 22 (12)
Mastectomy 44 (24)
Perceived preference of physician —
BCT 85 (47%)
Has no preference 74 (41%)
Mastectomy 19 (11%)
aMissing data for six patients (3%).
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about the decision made was collected at 3-months follow-up and
checked in the patients’ charts.
Analysis
Descriptive statistics were used to explore the relationships
between patients’ treatment preferences, treatment decisions, and
possible predictor variables. Bivariate associations were tested
through w
2 tests, Students’ t-tests and analysis of variance.
The effects of predictor variables, treatment preferences and the
decision aid on the treatment decision were further investigated
through structural equation modelling (Bollen, 1998). We hypo-
thesised a model in which the predictor variables either have direct
effects on the treatment decision, or have indirect effects mediated
by treatment preference (Figure 2). To reduce the number of
possible predictor variables, we first carried out linear regression
analyses of treatment preference, and logistic regression analyses
of treatment decision. The significance level for inclusion of predictors
was liberally set at 15%, to not miss any variable that might turn
out important in the subsequent structural equation modelling.
The fit of the structural equation model to the correlation matrix,
consisting of product–moment, biserial and point–biserial correla-
tion coefficients, was evaluated with the w
2-test of overall goodness-
of-fit, that is, the robust weighted least-squares goodness-of-fit
test (Satorra, 1992; Muthe ´n and Muthe ´n, 1998). After obtaining a
model with good fit, indicated by a nonsignificant w
2-value, para-
meter estimates were interpreted. Effects on treatment preference
and treatment decision are interpreted in the same way as in
ordinary linear regression analysis and probit regression analysis.
RESULTS
Patients
In total, 189 women were eligible for the study. Nine decided not to
participate (95% response rate). Informed consent was given by all
remaining patients (n¼180). All patients were treated with either
BCT or MT between 1996 and 1999. In the decision aid condition,
92 patients were included, and in the standard information
condition 88. Eight women were lost to follow-up at 3 months
because they were too ill (n¼3), died (n¼1) or were no longer
motivated (n¼3). Table 2 presents the patients’ background.
Treatment preference and treatment decision
BCT was the preferred treatment for 114 patients (63%) (Table 2).
MT was preferred by 44 patients (24%). Overall, 22 patients
(12%) felt unsure about their preference. Eventually, of 172
women, 123 (72%) decided to have BCT and 49 (28%) MT.
Treatment preference and decision were strongly associated
(w
2¼80.5; df¼4; Po0.001; Table 3). For example, of 82 patients
with a preference for BCT at baseline, 90% actually chose this
treatment option. Of the patients with a preference for MT, 85%
decided to have MT. Of 22 patients who felt unsure about their
treatment preference, 15 (68%) decided to undergo BCT and four
(18%) MT.
Predictors of treatment preference
Of socio-demographic variables, age was the only one found to be
related to treatment preference (Table 4); younger patients were
more likely to prefer BCT. Most generic and breast cancer-specific
Treatment 
decision
Treatment 
preference
Decision
aid
Work
Children 
at home Age Education Breast 
symptoms
Energy
Concern loss
of breast
Concern local 
recurrence Perceived 
preference 
of physician
0.44**
0.38**
0.79**
0.15 (NS)
0.37**
0.33**
0.11*
-0.33**
-0.09*
0.13**
0.24** 0.67**
0.12**
0.33**
Aversion
radiation 
Figure 2 Prediction of treatment preference and decision. Sample size¼172; goodness-of-fit: w
2¼8.9, degrees of freedom¼8, P¼0.35; for regression
coefficients: *denotes Po0.15; **¼Po0.05. Interpretation: All numbers represent standardised regression coefficients. For example, the  0.33 effect of
’’concern loss of breast’ on ‘treatment preference’ means that an increase in ‘concern’ of one standard deviation (s.d.) is associated with a decrease of 0.33
s.d. in ‘treatment preference’. Moreover, the 0.79 effect of ‘treatment preference’ on ‘treatment decision’ means that an increase of 1 s.d. in ‘treatment
preference’ is associated with a 0.79 increase in the probit of ‘treatment decision’. That is, for example, an increase in BCT probability from 50 to 82%.
Through ‘treatment preference’, ‘concern loss of breast’ has an indirect effect on ‘treatment decision’ which equals  0.33 0.79¼ 0.26.
Table 3 Treatment preference and treatment decision
Treatment Decision (n¼172)
BCT (n;% ) M T( n;% )
Treatment preference (n; %)
Definitely BCT 82 (46) 74 (90) 07 (09)
Probably BCT 32 (18) 26 (81) 03 (09)
Unsure 22 (12) 15 (68) 04 (18)
Probably MT 17 (09) 04 (24) 12 (71)
Definitely MT 27 (15) 04 (15) 23 (85)
180 123 (72%) 49 (28%)
Eight patients were lost at follow-up (see text for details). w
2¼80.5; df¼4; Po0.001.
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lQL variables were found to be related to treatment preference
(Table 5): patients with a more favourable QL preferred to have
BCT. Patients who expressed more concern regarding the loss of a
breast also preferred BCT. Conversely, patients who felt more
aversion to radiation, and expressed a higher level of concern
regarding local tumour recurrence, preferred MT. Wanting to
defer responsibility was associated with uncertainty regarding
treatment preference. There was no difference in avoidance,
information seeking and deliberation between patients favouring
BCT or MT. A higher level of decision uncertainty was associated
with an uncertain treatment preference. Yet, there was no relation
between ‘factors contributing to uncertainty’ and treatment
preference. Patients’ treatment preference was related to what
patients assumed to be their surgeons’ preferred treatment option.
Finally, having had the decision aid was not associated with the
treatment preference (Table 6).
Predictors of the treatment decision
Socio-demographic variables (Table 4) were not associated with
the treatment decision in the univariate analysis, nor were QL-
variables, except for having breast symptoms (Table 5): patients
with more breast symptoms were more likely to want to undergo
MT. Concern regarding the loss of a breast was related to BCT.
Conversely, concern about local tumour recurrence was associated
with MT. Aversion of radiation was not predictive of treatment
selection. No relations were found between decision style,
decisional conflict and the treatment decision. The treatment
decision was related however, to what patients perceived to be
their surgeons’ preference. Having seen a decision aid was also not
associated with the treatment choice (Table 6).
A model of treatment preference and decision making
Linear regression analysis predicting treatment preference yielded
a first selection (Pp0.15) of eight predictor variables, by both
forward and backward selection: age; education; breast symptoms;
energy; concern regarding the loss of the breast; concern for
local tumour recurrence; aversion to radiation; and perceived
preference of the surgeon. Information seeking and deliberation
were selected by backward selection only.
Logistic regression analysis predicting the treatment decision
yielded a second selection including the hospital involved; age;
education; having children; caring for (a) child(ren) at home; being
employed; concern about local recurrence; decision uncertainty
and treatment preference. We hypothesised that variables of the
second selection, that were not in the first selection, have direct
effects on treatment decision. Variables that were included in both
selections, such as concern about local tumour recurrence, were
hypothesised to have indirect effects on treatment decision,
mediated by treatment preference.
The overall goodness-of-fit of the resulting model was good
(robust weighted least squares; w
2¼12.6; df¼11; P¼0.32).
However, inspection of the parameter estimates showed that
the regressions of treatment preference on deliberation and
information seeking, and the regressions of treatment decision
on hospital, decision uncertainty and study-condition were
all insignificant (P40.10). Moreover, inspection of residuals
and first derivatives showed that in addition to indirect effects,
mediated by treatment preference, age and education also
had direct effects on treatment decision. Step-by-step modification
of the original model led to the model presented in Figure 2.
We retained having seen the decision aid or not in the modi-
fied model despite its insignificant effect on treatment decision,
because of its prime role in the research questions formu-
lated. The fit of this model to the data is good (w
2¼8.9; df¼8;
P¼0.35). The model explains 61% of the variance of treatment
preference, and 62% of the variance of (the probit of) treatment
decision.
What patients thought to be the treatment preference of their
surgeon was clearly found to be the best predictor (b¼0.37) of
their own treatment preference. More concern regarding the loss of
a breast (b¼ 0.33) was found to be a strong predictor of a
preference for BCT. Conversely, more concern for local tumour
recurrence (b¼0.33) and more aversion to radiation (b¼0.11)
were predictive of a preference for MT. Higher age was
significantly related to a preference for MT (b¼0.24). Of QL-
related predictors, more breast symptoms (b¼0.13) and less
energy (b¼ 0.09) were predictive of a preference for MT.
Table 4 Socio-demographic characteristics, by Treatment Preference and Treatment Decision
Treatment preference Treatment decision
Demographic characteristics BCT (n¼111/114) Unsure (n¼21/22) MT (n¼43/44) P BCT (n¼120/123) MT (47/49) P
Hospital 0.87 0.50
NKI 66% (59) 12% (11) 21% (19) 71% (60) 29% (25)
St Anna 63% (29) 11% (05) 26% (12) 78% (35) 22% (10)
MST 58% (26) 13% (06) 29% (13) 67% (28) 33% (14)
Age (year7s.d.) 52.9 (10.2) 55.8 (10.2) 59.9 (10.6) o0.01 53.5 (10.0) 58.4 (11.8) 0.07
Education 0.65 0.73
ocompulsory 63% (10) 19% (03) 19% (03) 80% (12) 20% (03)
Compulsory 61% (60) 11% (11) 28% (27) 72% (67) 28% (26)
Compulsory; ouniversity 69% (24) 17% (06) 14% (05) 73% (24) 27% (09)
University 65% (20) 07% (02) 29% (09) 65% (20) 36% (11)
Married/with partner 62% (73) 13% (16) 25% (30) 0.69 74% (83) 27% (30) 0.44
Not married/no partner 67% (41) 10% (06) 23% (14) 68% (40) 32% (19)
Has child(ren) 62% (91) 12% (18) 26% (39) 0.43 71% (100) 29% (41) 0.72
No child(ren) 72% (23) 13% (04) 16% (05) 74% (23) 26% (08)
Has child(ren) at home 67% (44) 14% (09) 20% (13) 0.44 69% (44) 31% (20) 0.48
No child(ren) at home 62% (67) 10% (11) 28% (30) 74% (76) 26% (27)
Lives alone 64% (28) 11% (05) 25% (11) 0.98 67% (29) 33% (14) 0.50
Lives with spouse/partner 63% (86) 13% (17) 24% (33) 73% (94) 27% (35)
Is employed 68% (66) 09% (09) 23% (22) 0.29 69% (64) 31% (29) 0.40
Not employed 58% (48) 16% (13) 27% (22) 75% (59) 25% (20)
P-values derived from Pearson’s w
2, except for age where P-value is derived from t-tests and analysis of variances (ANOVA).
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lAn important predictor of the treatment decision was the
patients’ previously expressed treatment preference (b¼0.79).
Higher age (b¼0.67), being employed (b¼0.44); having to care
for children (b¼0.38) and higher educational level (b¼0.33),
were directly predictive of a choice for MT.
DISCUSSION
The aim of the present study was to provide insight into the
treatment decision-making process of patients with early stage
breast cancer. Data were collected prospectively. Patients were
clinically eligible for both BCT and MT and were offered to choose
between both treatment options. Most patients (63%) preferred to
be treated with BCT, whereas one-quarter (24%) preferred MT,
and some (12%) felt unsure about their preferred treatment.
Subsequently, 90% of the patients chose the type of surgery they
initially preferred; 72% chose BCT and 28% MT. This is
comparable to the rate of BCT reported by Whelan et al (1999).
In their study, 73% of patients with a choice opted for BCT after
the introduction of a decision aid. Thus, not all women eligible for
a choice between BCT and MT want BCT.
Investigating the relative importance of different predictors of
treatment preference and the treatment decision resulted in a
model with good predictive qualities (Figure 2). What patients
thought to be the treatment preference of their physician was
found to be the most important predictor of their own treatment
preference. Likewise, previous studies also found that physicians
are a major factor in the treatment decisions made for breast
cancer (Ward et al, 1989; Kotwall et al, 1996; Stafford et al, 1998;
Table 5 QoL, attitudes, decision style, decisional conflict, perceived physician preference by treatment preference and decision
Treatment preference Treatment decision
Variable BCT (n¼108/114) Unsure (n¼22) MT (n¼44) P BCT (n¼117/123) MT (n¼46/49) P
Generic QoL
General health 61.0 (23.6) 53.8 (24.1) 51.8 (23.9) 0.07 59.5 (24.2) 54.1 (23.9) 0.19
Physical functioning 87.5 (18.0) 77.4 (23.6) 95.9 (28.5) o0.01 85.2 (20.0) 78.9 (27.3) 0.10
Pain 13.5 (17.9) 24.5 (23.0) 24.1 (23.1) o0.01 15.8 (19.2) 20.0 (22.0) 0.21
Role functioning 84.4 (28.5) 67.0 (42.5) 73.9 (35.7) 0.03 81.1 (31.9) 76.0 (34.6) 0.36
Social functioning 89.3 (20.1) 78.2 (29.5) 76.4 (31.5) o0.01 86.8 (22.3) 80.0 (31.4) 0.11
Psychological functioning 59.6 (21.6) 59.3 (22.2) 56.1 (22.0) 0.66 58.8 (20.9) 58.8 (24.3) 0.99
Energy 67.8 (23.1) 61.8 (24.2) 58.5 (19.9) 0.06 66.8 (23.2) 61.6 (21.6) 0.18
Breast cancer-specific QoL
Body image 92.4 (12.4) 92.0 (14.7) 85.6 (18.8) 0.03 91.2 (14.4) 89.8 (15.9) 0.58
Sexual functioning 28.4 (22.9) 17.4 (18.2) 19.5 (25.0) 0.03 26.8 (22.6) 21.0 (24.5) 0.15
Breast symptoms 13.7 (14.6) 21.6 (22.1) 22.0 (14.8) o0.01 15.0 (16.0) 20.4 (15.0) 0.05
Future perspective 50.6 (30.3) 39.4 (30.2) 43.2 (30.1) 0.17 47.7 (30.7) 47.6 (28.9) 0.99
Attitudes treatment outcomes
Concern loss of breast (1–10) 8.4 (2.5) 6.2 (3.1) 6.3 (3.3) o0.01 8.0 (2.7) 6.5 (3.3) o0.01
Aversion radiation (1–10) 6.2 (2.4) 6.6 (2.2) 7.4 (2.6) 0.03 6.4 (2.4) 6.8 (2.6) 0.29
Concern local recurrence (1–5) 3.4 (1.0) 3.8 (0.9) 4.6 (0.6) o0.01 3.5 (1.0) 4.3 (0.9) o0.01
Decision style
Avoidance 21.0 (18.0) 22.5 (21.6) 23.5 (20.3) 0.75 21.5 (19.4) 21.8 (17.4) 0.94
Defer responsibility 83.0 (17.0) 75.4 (20.0) 84.0 (17.2) 0.14 82.7 (16.7) 81.8 (19.5) 0.77
Information seeking 56.5 (29.1) 57.3 (34.0) 54.8 (28.1) 0.93 56.0 (30.3) 56.3 (26.4) 0.96
Deliberation 87.4 (16.7) 87.3 (17.8) 89.8 (13.2) 0.69 87.4 (16.5) 89.3 (15.1) 0.50
Decisional conflict
Decision uncertainty 2.6 (1.1) 3.7 (0.8) 2.7 (1.2) o0.01 2.8 (1.1) 2.6 (1.1) 0.25
Factors contributing uncertainty 2.5 (0.7) 2.8 (0.8) 2.3 (0.6) 0.06 2.5 (0.8) 2.4 (0.7) 0.54
Perceived preference physician o0.01* o0.01
**
Physician prefers BCT 82% (70) 12% (10) 06% (05) 87% (72) 13% (11)
Physician has no preference 54% (40) 14% (10) 32% (24) 68% (46) 32% (22)
Physician prefers MT 16% (03) 11% (02) 74% (14) 21% (04) 79% (15)
*w
2 45.9; df 4. **w
2 33.9; df 2.
Table 6 Study condition by treatment preference and treatment decision
Treatment preference Treatment decision
BCT (n¼114) Unsure (n¼22) MT (n¼44) P BCT (n¼123) MT (n¼49) P
Patient education 0.20 0.37
Decision aid 59% (54) 16% (15) 25% (23) 74% (67) 26% (23)
Standard information 68% (60) 08% (07) 24% (21) 68% (56) 32% (26)
P-values derived from Pearson’s w
2.
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lCyran et al, 2001; Nold et al, 2001). Patients are often inclined to
believe that they lack the knowledge and expertise to decide for
themselves, that the physician has additional information not (yet)
being shared, and that having confidence in the physician means
having confidence in their recommendation (Charavel et al, 2001;
Gurmankin et al, 2002). Moreover, patients may believe that being
in agreement with the physician is the best guarantee of getting a
good treatment. In this respect, there may be a tendency for
patients’ to assign their own treatment preference to the physician,
as she may want to believe they are in agreement.
Another key finding of our study is that the patients’ concern
about local recurrence was found to be an important predictor of a
preference and decision for MT. When patients want to minimise
their risk for local cancer recurrence, a decision to have MT will
indeed address their concern best. However, some patients may
inaccurately think that their chance to survive cancer improves
when choosing MT. In the long run, this decision may lead to
regret when patients learn that the benefit in survival they had
wanted, was not gained with MT.
Also, patients’ treatment preferences were strongly influenced
by the patients’ concern regarding the loss of a breast, and,
to a lesser extent, by their level of breast symptoms, energy
and aversion to radiation. These issues related to QL should be
addressed foremost in discussions between patients and physicians
while deciding upon treatment.
Socio-demographic factors were relatively important in our
study. Higher age was predictive of MT. This association has been
reported before, even though older women tolerate radiation well,
and have excellent control rates (Sakorafas and Tsiotou, 2000). The
higher rate of MT observed in older patients may reflect a
reluctance of women to undertake the extra visits to the radiation
clinic, required to complete BCT, a point of issue also suggested by
Staradub et al (2002).
Moreover, higher education was associated with MT, while
previous studies found a higher level of education to be associated
with BCT (Cyran et al, 2001; Gilligan et al, 2002). It has been
suggested that patients with higher education would be better able
to understand information regarding recurrence and overall
survival and would, as a result, accept BCT more frequently
(Cyran et al, 2001). The reasons for the association between
education and MT in the present study are unknown.
Employed women were more likely to have MT. In a study by
Staradub et al (2002) an insignificant trend was observed for
women with a job to select BCT. However, previous studies found
that patients with higher incomes and those having private
insurance were more likely to be treated by BCT (Gilligan et al,
2002; Morrow et al, 2001). Moreover, having to care for children
was also associated with MT. Possibly, in the present study,
working women and those caring for children were unable to fulfil
BCT, which includes 5–6 weeks of daily radiation, due to their
duties at work or as a parent. Having to undergo radiation does
indeed take a good deal of energy and time from the patient.
The use of a decision aid did not influence the kind of treatment
selected. This is a desirable outcome as the aim of the decision aid
is to assist patients in the decision-making process, and not to
prescribe a course of action. The value of decision aids for breast
cancer treatment decision making is increasingly being acknowl-
edged (Goldhirsch et al, 2003). Nevertheless, from the current and
previous studies it seems clear that patients rely heavily upon their
surgeon also for guidance.
Some limitations of our study may be mentioned. Patients’
treatment preferences may be influenced by factors not acknowl-
edged in this study, for example, the size of the tumour; disease
stage; patients’ ethnic or cultural background; preferences of a
partner or members of the family; fellow patients; and influences of
the media, and other health professionals, for example, nurses,
radiation physician, family physician.
Moreover, the administration of the baseline questionnaire may
have heightened patients’ awareness, and may have influenced
certain predictor variables. For example, it may have raised
patients’ concern of cancer recurrence or radiation.
It has been frequently documented that many breast cancer
patients want to share treatment decision making with their
physician (Bruera et al, 2002). Given our results, practical
suggestions as to how physicians could effectively decide upon
treatment with their patients can be made. Although a strong
influence of physicians on patients’ decisions does not necessarily
mean that patients’ values are disregarded, physicians might try
consciously not to impose their own treatment preference on
patients. To prevent physicians from exerting too much influence,
we suggest that they carefully plan the timing of the communica-
tion of their own treatment preference. Prior to giving a treatment
preference, surgeons may first have to, neutrally, provide unbiased
information concerning both treatments. Decision aids can
assist in this information-giving stage. Thereafter, special attention
should be given to patients’ concerns and the clarification of
their values. Explicitly addressing patients’ understanding of
concerns regarding local recurrence and radiation may identify
inaccurate beliefs; prevent unfounded fears and ‘irrational’
treatment preferences. It is important to notice that, even when
adequately informed, some patients may still favour MT as a
means to cope with a more general fear of cancer. Moreover,
patients’ concerns for breast loss and breast symptoms are
important topics to be addressed in discussions about treatment.
After patients’ concerns have sufficiently been discussed, physi-
cians might first only ask patients to express a treatment
preference. Rather than providing advice from the start, physicians
might then communicate their own treatment preference, or give a
treatment recommendation that accounts for the concerns of the
individual patient.
Engaging patients in treatment decision making, and refraining
from too much influencing the patient is a difficult task (Charavel
et al, 2001). It does not only require time, but effective
communication skills also. The current study helps to select those
issues that need attention, and may thus contribute to efficient and
effective decision making in early breast cancer.
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